HOME >> BIOLOGY >> NEWS
Fighting diabetes: UD researchers move closer to chip-based control of 'smart,' implantable insulin pumps

d blood-sugar levels that can occur after a diabetic patient eats," he explains.

As a result, he says, patients may experience many hours of very high or low sugar levels before returning to a normal state.

The UD system more precisely controls blood sugar by constantly predicting the patient's need for insulin. Based on a mathematical model of the human glucose-insulin system, the algorithms analyze data from past events to forecast future insulin requirements.

And, because the algorithms are "linear," or simplified to approximate the function of the gut, the pancreas and other portions of body systems, they could be maintained on a tiny computer chip, Doyle says.

His approach, based on "model predictive control with state estimation" (MPCSE) algorithms, effectively reduced peak glucose levels by 44 percent, in computer simulations, compared to algorithms published in scholarly literature.

The system also reduced by 80 percent the "overshoot," or degree to which blood-sugar levels rose above a targeted range of 81 mg/dl, compared to patients with uncontrolled diabetes, Parker says. Small delays in receiving data from glucose sensors didn't seem to impair the performance of the UD system, which demonstrated a settling time of about 4.5 hours.

Doyle predicts that "smart" implantable insulin pumps won't become available to patients for another three to five years, even with FDA approval. But, he says, research presented at the AAMI meeting confirms the viability of this promising new technology.

Someday, he says: "Automatically controlled, implantable insulin delivery systems will no longer be science fiction."


'"/>

Contact: Ginger Pinholster
gingpin@udel.edu
302-831-6408
University of Delaware
6-Jun-1999


Page: 1 2 3

Related biology news :

1. Fighting Mycobacterium tuberculosis with structural proteomics
2. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
3. Fighting the spread of sudden oak death
4. Fighting the battle of the bulge in children
5. Fighting breast cancer at the molecular level
6. Fighting Fungi
7. Fighting skin cancers with computers and technology
8. Trash From Crop-Processing Plant Harvested For Disease-Fighting Agents
9. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
10. Chemical Contaminants May Inhibit Cancer-Fighting White Blood Cells
11. Radioactive Beads Latest Weapon In Fighting Cancer In Dogs, Cats

Post Your Comments:
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: